NCT07314190Enrolling by invitation
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
Synapsing Retrospective Biomarker Study
Source: ClinicalTrials.gov · Last updated 23 Feb 2026
Brief summary (registry, in English)
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 1799 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 19 Feb 2026
- Primary completion date
- 30 Jun 2029
- Lead sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Diseases
- Frontotemporal dementia, Lewy body dementia, Depression, Bipolar disorder, Alzheimer disease, Parkinson disease
- NCT number
- NCT07314190
What you commit to
- Study type: Observational
- Planned participants: 1799
- From 19 Feb 2026 to the primary completion date, 30 Jun 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- anticoagulant treatment such as acenocoumarol, heparin, warfarin, dabigatran, rivaroxaban, apixaban, drug abuse in the last year,
- the patient has received potentially neurotoxic chemotherapy and/or patient has received cranial radiotherapy.
Other illness
- medical history of cancer affecting the central nervous system that has not been in complete remission for 5 years or longer,
- Clinical diagnosis of Alzheimer's disease where pathophysiological markers (measured in CSF or plasma) are inconsistent with Alzheimer's disease pathophysiology.
- Cognitively healthy volunteers where pathophysiological markers (measured in CSF or plasma) are consistent with Alzheimer's disease or other neurodegenerative pathophysiology.
Other
- Lack of neuropsychological data,
Who the study is looking for
- Age\>18 and donation of blood,
- full clinical and psychological assessment
- Available neuroimaging is optional as not all patients are suitable.
- Age and sex-matched unaffected volunteers without a MD or ND diagnosis are used as controls.
- Unaffected controls are usually spouses or children of patients that are informed about our studies at each clinical site.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - IIB Sant Pau Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.